Drug Trial Radar · NCT05104567
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Dec 9, 2021
Primary completion
Jul 26, 2023
Study completion Sep 9, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer. This study is structured as a master protocol for the investigation of SAR444245 with other anticancer therapies. Sub study 01 - Cohort A aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Sub study 02 - Cohort B1, B2 and B3 would focus on non MSI-H tumors with a large unmet need to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), especially with low PD-L1 expression or after progression on prior PD1/PD-L1-based regimens. Sub study 03 - Cohort C aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in participants with advanced unresectable or metastatic HCC who relapsed on prior PD1/PD-L1-based regimens. Sub study 04 - Cohort D1 and D2 aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with either the anti-PD1 antibody pembrolizumab or with the anti-EGFR IgG1 antibody cetuximab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic colorectal cancer (mCRC).
Conditions
- Oesophageal Squamous Cell Carcinoma
- Gastric Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Oesophageal Adenocarcinoma
Interventions
THOR-707Drug
Solution for infusion: intravenous infusion
PembrolizumabDrug
Solution for infusion: intravenous infusion
CetuximabDrug
Solution for infusion: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Objective Response Rate (ORR)Time frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 8 months
- Cohorts B1, B2 and B3: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 25 months
- Cohort C: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 20 months
- Cohorts D1 and D2: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 8 months
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
City of Hope Site Number : 8400007
Duarte, California
AdventHealth Orlando Site Number : 8400005
Orlando, Florida
Seattle Cancer Care Alliance Site Number : 8400009
Seattle, Washington
Investigational Site Number : 0560002
Brussels, Belgium
Investigational Site Number : 0560003
Edegem, Belgium
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1560002
Wuhan, China
Investigational Site Number : 2500004
Bordeaux, France
Investigational Site Number : 2500006
Brest, France
Investigational Site Number : 2500002
Paris, France
Investigational Site Number : 2500005
Poitiers, France
Investigational Site Number : 2500001
Villejuif, France
Investigational Site Number : 3800003
Milan, Italy
Investigational Site Number : 3800002
Milan, Italy
Investigational Site Number : 3800001
Rozzano, Lombardy, Italy
Investigational Site Number : 5280001
Amsterdam, Netherlands
Investigational Site Number : 5280003
Rotterdam, Netherlands
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100004
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100003
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240006
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240005
Santander, Cantabria, Spain
Investigational Site Number : 7240101
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240003
Madrid / Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240004
Madrid / Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240001
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.